Nutraceutical-mediated restoration of wild-type levels of IKBKAP-encoded IKAP protein in familial dysautonomia-derived cells

Molecular Nutrition and Food Research

Volumn 56, Issue 4, 2012, Pages 570-579

  Anderson, Sylvia L ^a   Liu, Bo ^a   Qiu, Jinsong ^a,b   Sturm, Andrea J ^a   Schwartz, Jamie A ^c   Peters, Austin J ^a   Sullivan, Kerry A ^a   Rubin, Berish Y ^a  

^a FORDHAM UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Alternative splicing; Familial dysautonomia; Genistein; Isoflavone; Nutraceutical

Indexed keywords

CARRIER PROTEIN; CATECHIN; DAIDZEIN; DRUG DERIVATIVE; EPIGALLOCATECHIN GALLATE; GENISTEIN; IKBKAP PROTEIN, HUMAN; INOSITOL HEXAKISPHOSPHATE KINASE; ISOFLAVONE DERIVATIVE; PHOSPHOTRANSFERASE;

ARTICLE; CELL STRAIN HEK293; CYTOLOGY; DIET SUPPLEMENTATION; DRUG EFFECT; DRUG POTENTIATION; DYSAUTONOMIA; FIBROBLAST; GENETICS; GENOTYPE; HUMAN; METABOLISM; NERVE CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SPLICING; UPREGULATION; WESTERN BLOTTING;

BLOTTING, WESTERN; CARRIER PROTEINS; CATECHIN; DIETARY SUPPLEMENTS; DRUG SYNERGISM; DYSAUTONOMIA, FAMILIAL; FIBROBLASTS; GENISTEIN; GENOTYPE; HEK293 CELLS; HUMANS; ISOFLAVONES; NEURONS; PHOSPHOTRANSFERASES (PHOSPHATE GROUP ACCEPTOR); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA SPLICING; UP-REGULATION;

EID: 84859749804     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201100670     Document Type: Article

References (57)

1. Riley, C. M., Day, R. L., Greely, D., Langford, W. S., Central autonomic dysfunction with defective lacrimation. Pediatrics 1949, 3, 468-477.
2. Axelrod, F. B., Nachtigal, R., Dancis, J., Familial dysautonomia: diagnosis, pathogenesis and management. Adv. Pediatr. 1974, 21, 75-96.
3. Axelrod, F. B., in: Robertson, D., Low, P. A., Polinsky, R. J. (Eds.), Primer on the Autonomic Nervous System, Academic Press, San Diego 1996, pp. 242-249.
4. Rubin, B. Y., Anderson, S. L., The molecular basis of familial dysautonomia: overview, new discoveries and implications for directed therapies. Neuromol. Med. 2008, 10, 148-156.
5. Anderson, S. L., Coli, R., Daly, I. W., Kichula, E. A. et al., Familial Dysautonomia is caused by mutations of the IKAP gene. Am. J. Hum. Genet. 2001, 68, 753-758.
6. Slaugenhaupt, S. A., Blumenfeld, A., Gill, S. P., Leyne, M. et al., Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. Am. J. Hum. Genet. 2001, 68, 598-605.
7. Cohen, L., Henzel, W. J., Baeuerle, P. A., IKAP is a scaffold protein of the IΚB kinase complex. Nature 1998, 395, 292-297.
8. Otero, G., Fellows, J., Li, Y., de Bizemont, T. et al., Elongator, a multisubunit component of a novel RNA polymerase II holoenzyme for transcriptional elongation. Mol. Cell 1999, 3, 109-118.
9. Krappmann, D., Hatada, E. N., Tegethoff, S., Li, J. et al., The IΚB kinase (IKK) complex is tripartite and contains IKKγ but not IKAP as a regular component. J. Biol. Chem. 2000, 275, 29779-29787.
10. Hawkes, N. A., Otero, G., Winkler, G. S., Marshall, N. et al., Purification and characterization of the human elongator complex. J. Biol. Chem. 2002, 277, 3047-3052.
11. Holmberg, C., Katz, S., Lerdrup, M., Herdegen, T., et al., A novel specific role for I kappa B kinase complex-associated protein in cytosolic stress signaling. J. Biol. Chem. 2002, 35, 31918-31928.
12. Rahl, P. B., Chen, C. Z., Collins, R. N., Elp1p, the yeast homolog of the FD disease syndrome protein, negatively regulates exocytosis independently of transcriptional elongation. Mol. Cell. 2005, 17, 841-853.
13. Chen, Y. T., Hims, M. M., Shetty, R. S., Mull, J. et al., Loss of mouse Ikbkap, a subunit of elongator, leads to transcriptional deficits and embryonic lethality that can be rescued by human IKBKAP. Mol. Cell. Biol. 2009, 29, 736-744.
14. Mehlgarten, C., Jablonowski, D., Wrackmeyer, U., Tschitschmann, S. et al., Elongator function in tRNA wobble uridine modification is conserved between yeast and plants. Mol. Microbiol. 2010, 76, 1082-1094.
15. Cheishvili, D., Maayan, C., Cohen-Kupiec, R., Lefler, S. et al., IKAP/Elp1 involvement in cytoskeleton regulation and implication for familial dysautonomia. Hum. Mol. Genet. 2011, 20, 1585-1594.
16. Anderson, S. L., Qiu, J., Rubin, B. Y., Tocotrienols induce IKBKAP expression: a possible therapy for familial dysautonomia. Biochem. Biophys. Res. Commun. 2003, 306, 303-309.
17. Anderson, S. L., Rubin, B. Y., Tocotrienols reverse IKAP and monoamine oxidase deficiencies in familial dysautonomia. Biochem. Biophys. Res. Commun. 2005, 336, 150-156.
18. Gold-von Simson, G., Axelrod, F. B., Familial dysautonomia: update and recent advances. Curr. Probl. Pediatr. Adolesc. Health Care 2006, 36, 218-237.
19. Rubin, B. Y., Anderson, S. L., Kapás, L., Can the therapeutic efficacy of tocotrienols in neurodegenerative familial dysautonomia patients be measured clinically? Antioxid. Redox. Signal. 2008, 10, 837-841.
20. Anderson, S. L., Qiu, J., Rubin, B. Y., EGCG corrects aberrant splicing of IKAP mRNA in cells from patients with familial dysautonomia. Biochem. Biophys. Res. Commun. 2003, 310, 627-633.
21. Slaugenhaupt, S. A., Mull, J., Leyne, M., Cuajungco, M. P. et al., Rescue of a human mRNA splicing defect by the plant cytokinin kinetin. Hum. Mol. Genet. 2004, 13, 429-436.
22. Keren, H., Donyo, M., Zeevi, D., Maayan, C. et al., Phosphatidylserine increases IKBKAP levels in familial dysautonomia cells. PLoS One 2010, 5, e15884.
23. Rubin, B. Y., Anderson, S. L., Sullivan, S. A., Williamson, B. D. et al., Purification and characterization of a human tumor necrosis factor from the LuKII cell line. Proc. Natl. Acad. Sci. USA 1985, 82, 6637-6641.
24. Rasband, W. S., Image J, U.S. National Institutes of Health, Bethesda, MD, USA, 1997-2011.
25. Ladd, A. N., Cooper, T. A., Finding signals that regulate alternative splicing in the post-genomic era. Genome Biol. 2002, 3, reviews0008.1-reviews0008.16.
26. Zheng, Z. M., Regulation of alternative RNA splicing by exon definition and exon sequences in viral and mammalian gene expression. J. Biomed. Sci. 2004, 11, 278-294.
27. Johnson, J. M., Castle, J., Garrett-Engele, P., Kan, Z. et al., Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 2003, 302, 2141-2144.
28. Stenson, P. D., Ball, E. V., Mort, M., Phillips, A. D. et al., Human gene mutation database (HGMD): 2003 update. Hum. Mutat. 2003, 21, 577-581.
29. López-Bigas, N., Audit, B., Ouzounis, C., Parra, G. et al., Are splicing mutations the most frequent cause of hereditary disease? FEBS Lett. 2005, 579, 1900-1903.
30. Lim, K. H., Ferraris, L., Filloux, M. E., Raphael, B. J. et al., Using positional distribution to identify splicing elements and predict pre-mRNA processing defects in human genes. Proc. Natl. Acad. Sci. USA 2011, 108, 11093-11098.
31. Axelrod, F. B., Liebes, L., Gold-von Simson, G., Mendoza, S. et al., Kinetin improves IKBKAP mRNA splicing in patients with familial dysautonomia. Pediatr. Res. 2011, 70, 480-483.
32. Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H. et al., Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 1987, 262, 5592-5595.
33. Akiyama, T., Ogawara, H., Use and specificity of genistein as inhibitor of protein-tyrosine kinases. Methods Enzymol. 1991, 201, 362-370.
34. Trieu, V. N., Uckun, F. M., Genistein is neuroprotective in murine models of familial amyotrophic lateral sclerosis and stroke. Biochem. Biophys. Res. Commun. 1999, 258, 685-688.
35. Zhao, L., Chen, Q., Diaz Brinton, R., Neuroprotective and neurotrophic efficacy of phytoestrogens in cultured hippocampal neurons. Exp. Biol. Med. 2002, 227, 509-519.
36. Bang, O. Y., Hong, H. S., Kim, D. H., Kim, H. et al. Neuroprotective effect of genistein against beta amyloid-induced neurotoxicity. Neurobiol. Dis. 2004, 16, 21-28.
37. Sonee, M., Sum, T., Wang, C., Mukherjee, S. K., The soy isoflavone, genistein, protects human cortical neuronal cells from oxidative stress. Neurotoxicology 2004, 25, 885-891.
38. Zeng, H., Chen, Q., Zhao, B., Genistein ameliorates beta-amyloid peptide (25-35)-induced hippocampal neuronal apoptosis. Free Radic. Biol. Med. 2004, 36, 180-188.
39. Azcoitia, I., Moreno, A., Carrero, P., Palacios, S., Garcia-Segura, L. M., Neuroprotective effects of soy phytoestrogens in the rat brain. Gynecol. Endocrinol. 2006, 22, 63-69.
40. Schreihofer, D. A., Redmond, L., Soy phytoestrogens are neuroprotective against stroke-like injury in vitro. Neuroscience 2009, 158, 602-609.
41. Altavilla, D., Crisafull, I. A., Marini, H., Esposito, M. et al., Cardiovascular effects of the phytoestrogen genistein. Curr. Med. Chem. Cardiovasc. Hematol. Agents 2004, 2, 179-186.
42. Rimbach, G., Boesch-Saadatmandi, C., Frank, J., Fuchs, D. et al., Dietary isoflavones in the prevention of cardiovascular disease-a molecular perspective. Food Chem. Toxicol. 2008, 46, 1308-1319.
43. Andersson, C., Roomans, G. M., Activation of deltaF508 CFTR in a cystic fibrosis respiratory epithelial cell line by 4-phenylbutyrate, genistein and CPX. Eur. Respir. J. 2000, 15, 937-941.
44. Schmidt, A., Hughes, L. K., Cai, Z., Mendes, F. et al., Prolonged treatment of cells with genistein modulates the expression and function of the cystic fibrosis transmembrane conductance regulator. Br. J. Pharmacol. 2008, 153, 1311-1323.
45. Piotrowska, E., Jakobkiewicz-Banecka, J., Maryniak, A., Tylki-Szymanska, A. et al., Two-year follow-up of Sanfilippo disease patients treated with a genistein-rich isoflavone extract: assessment of effects on cognitive functions and general status of patients. Med. Sci. Monit. 2011, 17, CR196-202.
46. Stamm, S., Regulation of alternative splicing by reversible protein phosphorylation. J. Biol. Chem. 2008, 283, 1223-1227.
47. Hartmann, A. M., Rujescu, D., Giannakouros, T., Nikolakaki, E. et al., Regulation of alternative splicing of human tau exon 10 by phosphorylation of splicing factors. Mol. Cell. Neurosci. 2001, 18, 80-90.
48. Allemand, E., Hastings, M. L., Murray, M. V., Myers, M. P. et al., Alternative splicing regulation by interaction of phosphatase PP2Cgamma with nucleic acid-binding protein YB-1. Nat. Struct. Mol. Biol. 2007, 14, 630-638.
49. Lin, L. C., Wang, M. N., Tseng, T. Y., Sung, J. S. et al., Pharmacokinetics of (-)-epigallocatechin-3-gallate in conscious and freely moving rats and its brain regional distribution. J. Agric. Food Chem. 2007, 55, 1517-1524.
50. Tsai, T. H., Concurrent measurement of unbound genistein in the blood, brain and bile of anesthetized rats using microdialysis and its pharmacokinetic application. J. Chromatogr. A. 2005, 1073, 317-322.
51. Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O. et al., Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995, 80, 155-165.
52. Lorson, C. L., Hahnen, E., Androphy, E. J., Wirth, B., A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl. Acad. Sci. USA 1999, 96, 6307-6311.
53. Monani, U. R., Lorson, C. L., Parsons, D. W., Prior, T. W. et al., A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum. Mol. Genet. 1999, 8, 1177-1183.
54. Lorson, C. L., Strasswimmer, J., Yao, J. M., Baleja, J. D. et al., SMN oligomerization defect correlates with spinal muscular atrophy severity. Nat. Genet. 1998, 19, 63-66.
55. Sakla, M. S., Lorson, C. L., Induction of full-length survival motor neuron by polyphenol botanical compounds. Hum. Genet. 2008, 122, 635-643.
56. Futaki, M., Yamashita, T., Yagasaki, H, Toda, T. et al., The IVS4 + 4 A to T mutation of the fanconi anemia gene FANCC is not associated with a severe phenotype in Japanese patients. Blood 2000, 95, 1493-1498.
57. Axelrod, F. B., Goldberg, J. D., Rolnitzky, L., Mull, J. et al., Fludrocortisone in patients with familial dysautonomia-assessing effect on clinical parameters and gene expression. Clin. Auton. Res. 2005, 15, 284-291.